GLPBio

TSPBA

Catalog No.: GC79921Purity:>99.50%
TSPBA is a bis-terminal phenylboronic acid-spacer diammonium salt crosslinker.

Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.


TSPBA
Cas No.: 2222566-33-6
5mgIn Stock
$342.00
1

Citations

Aucune citation n’est actuellement disponible pour ce produit. Vous trouverez ci-dessous une sélection de publications citant des produits GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

TSPBA is a bis-terminal phenylboronic acid-spacer diammonium salt crosslinker. TSPBA forms dynamic phenylboronate ester bonds with PVA, enabling the preparation of injectable self-healing hydrogels and endowing them with injectability, self-healing property, ROS-responsive degradation, tissue adhesion, and weak glucose-binding ability. TSPBA is applicable to research related to diabetic wounds [1].

In Vivo, TSPBA (3 w/v%; topical) -containing PATA hydrogel supports diabetic wound healing by scavenging ROS and exhibiting favorable biocompatibility with complete in vivo degradation by day 14, though optimal wound healing and primary blood glucose regulation require additional loaded agents in the PATA-GM (SF/LP) formulation[1].

In Vitro, TSPBA (3 w/v%; 2 days) containing PATA hydrogels disrupt MSSA, MRSA, and E. coli biofilms in vitro, as evidenced by SEM visualization of dispersed biofilms, with bacterial lysis restricted to SF-loaded hydrogel formulations[1]. TSPBA (3 w/v%; 2 h) containing PATA hydrogels scavenge over 60% of intracellular ROS in H2O2-stimulated L929 fibroblast cells in vitro[1]. TSPBA (3 w/v%; 24 h) containing PATA hydrogels do not reduce glucose concentrations in L929 fibroblast cell culture supernatants in vitro, while MH-loaded PATA hydrogel formulations do lower supernatant glucose levels[1].

References:
[1]. Chen R, et al. A multifunctional injectable, self-healing, and adhesive hydrogel-based wound dressing stimulated diabetic wound healing with combined reactive oxygen species scavenging, hyperglycemia reducing, and bacteria-killing abilities. Journal of nanobiotechnology. 2024 Jul 27;22(1):444.

Documents produit (Product Documents)

Purity:>99.50%Appearance:A solid

Propriétés chimiques (Chemical Properties)

N° CAS
2222566-33-6
Formule moléculaire
C21H34B2Br2N2O4
Masse moléculaire
559.94
Solubilité
H2O: ≥ 100 mg/mL (178.59 mM)
Conservation
Store at 4°C, away from moisture and light
Conditions d’expédition
Les échantillons d’évaluation sont expédiés avec des blocs réfrigérants. Les autres formats sont expédiés à température ambiante ou, sur demande, avec des blocs réfrigérants.

Calculateurs (Calculators)Molarité / Dilution / Masse moléculaire / Conversion d’unités / Formulation in vivo / Solubilité

g/mol

Reviews

Review for TSPBA

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%